{'fraction_non_alphanumeric': 0.030620467365028204, 'fraction_numerical': 0.016921837228041903, 'mean_word_length': 5.402061855670103, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preventive treatment of intrauterine device‐induced menstrual blood loss with tranexamic acid in Chinese women

Objectives. To investigate whether tranexamic acid (Transamin®) therapy reduces the amount of menstrual blood loss (MBL) and occurrence of menorrhagia after intrauterine device (IUD) insertion. Methods. Some 175 Chinese women attending for IUD insertion were equally assigned into 2 Transamin® groups (1,000 and 500 mg, twice daily) and a placebo group. Their MBL was recorded with a pictorial chart in 3 subsequent menstrual cycles after insertion, while the MBL of 64 patients, collecting used sanitary towels, was also measured by an alkaline hematin method. Results. A significant decline in post‐insertion MBL and occurrence of menorrhagia was found in the 2 Transamin® groups compared with the placebo group (p<0.05), whereas the difference in the results from the pictorial chart score was not statistically significant between the 1 g group and placebo group. Conclusion. Transamin® treatment with a generally recommended dosage can effectively reduce the amount of IUD‐induced MBL and prevent menorrhagia in Chinese women. A lower dosage than recommended (50% of recommended dosage) may have a similar preventive effect.